https://www.onhealthcare.tech/p/why-asco-stood-up-for-daraxonrasib-459Thoughts on Healthcare Markets & Technologyen2026-06-04T13:50:03+00:00Why ASCO Stood Up for Daraxonrasib: RASolute 302, Pancreatic Cancer Survival, and the New KRAS Investment Thesishttps://www.onhealthcare.tech/p/why-asco-stood-up-for-daraxonrasibThoughts on Healthcare Markets & Technologyen2026-06-04T13:35:58+00:00Why ASCO Stood Up for Daraxonrasib: RASolute 302, Pancreatic Cancer Survival, and the New KRAS Investment Thesishttps://www.onhealthcare.tech/p/inside-the-agentic-back-office-raceThoughts on Healthcare Markets & Technologyen2026-06-03T13:38:38+00:00Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collectionshttps://www.onhealthcare.tech/p/part-ii-inside-the-agentic-back-officeThoughts on Healthcare Markets & Technologyen2026-06-03T13:29:43+00:00Part II: Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collections Workhttps://www.onhealthcare.tech/p/part-i-inside-the-agentic-back-officeThoughts on Healthcare Markets & Technologyen2026-06-03T13:26:03+00:00Part I: Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collections